Healthcare Providers and Services
Company Overview of Henry Ford Health System, Inc.
Henry Ford Health System, Inc., a not-for-profit corporation, provides various healthcare services in the United States. It offers services in the areas of addiction treatment, allergy and immunology, anesthesiology, autism and developmental disabilities, bariatric surgery center, behavioral health, cancer, center for integrative medicine, colon and rectal surgery, dermatology, diabetes, emergency, family medicine, gastroenterology, general surgery, genetics, heart and vascular, brain tumor, hospital medicine, infectious diseases, and internal medicine; and endocrinology and bone mineral disorders. The company also provides services in the areas of liver cancer, nephrology and hypertension, ...
1 Ford Place
Detroit, MI 48202-3450
Founded in 1915
Key Executives for Henry Ford Health System, Inc.
Chief Executive Officer and Trustee
Acting Chief Financial Officer
Executive Vice President, Chief Executive Officer of Health Alliance Plan and President of Health Alliance Plan
Compensation as of Fiscal Year 2014.
Henry Ford Health System, Inc. Key Developments
Henry Ford Health System, Inc. Announces Management Changes
Sep 29 14
As part of a two-year succession plan, Nancy Schlichting, CEO of Henry Ford Health System, Inc. announced that she will retire in December 2016 and the appointment of a new president for the health system. Wright L. Lassiter, III, currently CEO at Alameda Health System in Oakland, California, will begin his new role as president of Henry Ford Health System on December 15, 2016. Lassiter is a seasoned CEO with 20 years of experience in large, complex health systems, including Methodist Health System in Dallas and JPS Health Network in Fort Worth, Texas. Lassiter in his most recent position as CEO at Alameda Health System (AHS) in Oakland, Calif., Lassiter led the expansion and turnaround of an $865 million public health system, achieving eight years of positive financial performance with operating margins as high as 19%.
Henry Ford Health System Launches Clinical Trial to Investigate New Drug for the Treatment of Tinnitus
Jun 24 14
Henry Ford Health System has launched a clinical trial to investigate a new drug for the treatment of tinnitus, a chronic ringing of the head or ears that affects more than 600 million people worldwide. The study will examine AM-101, a gel injected into the middle ear, to determine its safety and effectiveness in lessening the excessive signaling to the brain that occurs with acute inner ear tinnitus, most often caused by noise trauma or infection. AM-101 inhibits certain receptors in the inner ear that are thought to play a key role in the development of tinnitus. This inhibitory effect has been investigated and confirmed in animal behavior models. Tinnitus in the inner ear is often a consequence of an acoustic trauma, barotrauma, operation on the middle ear, traumatic perforation of the eardrum or middle ear infection. While the tinnitus often goes away after a short period in these circumstances, it can persist in some cases even after the injury has healed. For its study, Henry Ford will recruit patients who have experienced tinnitus for three months or fewer following traumatic cochlear injury or otitis media, an inflammation of the middle ear. In an outpatient procedure, the study drug AM-101 or a placebo will be injected into the middle ear, where it then passes into the inner ear, following the administration of a local anesthetic to the eardrum. The injection will be repeated two more times during a five-day period. Patients in the study also will need to return for several follow-up visits. Throughout the study, patients will be asked each evening to answer two short questions on the loudness of the tinnitus and the associated annoyance in an electronic diary. In order to investigate the efficacy of AM-101, it must be possible to compare the improvement in the tinnitus after the injection with a control group. Therefore, some of the participants will receive a placebo preparation. Neither the patient nor the study doctor will know who has received AM-101 or the placebo. Once the initial study is complete, all of the trial participants will have the opportunity to receive the study drug. Study participants The Henry Ford study is seeking patients, ages 18-75, who have been diagnosed within the past three months or less with acute inner ear tinnitus brought on by acoustic trauma, barotrauma, operation on the middle ear, traumatic perforation of the eardrum or middle ear infection. Those whose tinnitus has existed for more than three months, or was triggered by events other than traumatic cochlear injury or middle ear infection, may not take part in the study. Participants must agree to use hearing protection, refrain from engaging in activities or work involving loud noise exposure if sufficient hearing protection is not possible, and able to protect ear canal and middle ear from water exposure, as well as be willing to comply with all study-related procedures during the course of the clinical trial.
Henry Ford Health System, Inc. Presents at The Michigan Growth Capital Symposium, Jun-17-2014 03:40 PM
Jun 13 14
Henry Ford Health System, Inc. Presents at The Michigan Growth Capital Symposium, Jun-17-2014 03:40 PM. Venue: Marriott Resort at Eagle Crest, 1275 S. Huron Street, Ypsilanti, MI 48197, United States. Speakers: Kristyn Aalto, Director of Innovations.
Similar Private Companies By Industry
Recent Private Companies Transactions